Understanding Biosimilars: Intellectual Property Challenges

Goodwin Procter partners Theresa Kavanaugh, Duncan Greenhalgh, Elaine Herrmann Blais, and Daryl Wiesen will host this seminar which will address key similarities and differences between the biosimliar pathway and the Hatch-Waxman Act (ANDA) pathway for small molecules, differences in patent strategy for biologics small-molecule and small molecule drugs and biosimilar-specific licensing considerations.